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Microvesicles and exosomes have emerged
as a new mode of intercellular communi-
cation in cancer. In recent years, microvesi-
cles have received increasing attention from
the scientific community for their role in
regulating and transferring active mole-
cules responsible for tumor progression
and metastasis. Controversy arises from
the fact that microvesicles can transfer
tumor-promoting molecules such as onco-
proteins (1–3), and tumor suppressors (4,
5). So, how can we make sense of this
controversy?
By considering what we know of cancer
development, we can rectify the seemingly
opposing findings of the role of microvesi-
cles in this process. The role of oncogenes
in the progression of cancer is a well-
investigated matter, and it is known that
cancer progression is dependent on over-
expression or mutation of oncogenic pro-
teins. On the other hand, it also depends on
loss or downregulation of tumor suppres-
sor proteins.
The effect of the intercellular exchange
of oncoproteins and tumor suppressor
proteins through microvesicles on can-
cer progression most probably follows the
“Yin–Yang” concept. The availability of
microvesicles rich in oncoproteins or those
containing tumor suppressors will decide
the new phenotype characteristics acquired
by the acceptor cells. In the case of the
tumor suppressor PTEN, it is interesting to
note that metastases often have no expres-
sion of PTEN, although the primary tumor
itself expresses PTEN (6). This may indi-
cate that cells capable of initiating metas-
tasis originate from cellular selection (7),
whereby cells with little or no expression
of PTEN are more likely to initiate suc-
cessful metastases (8, 9). Furthermore, it
is known from a series of studies of two
tumor systems that tumors “talk” to each
other through serum-borne factors (10–
12). A tumor at one side of an experimental
animal can affect the dynamics of a tumor
on the other side. However, the serum-
borne factors suggested in these studies are
not fully defined; microvesicles represent
a reasonable candidate as a player in this
form of cellular communication. Such a
mode of cellular communication may have
a role in tumor metastasis.
Microvesicles that contain PTEN are
shed from primary PTEN-expressing
tumors to the bloodstream, and may rep-
resent the serum-borne factors that are
used by the primary tumor to affect
the growth of metastases not express-
ing PTEN. This may indicate a suc-
cessfully adopted mechanism through-
out the natural history of cancer devel-
opment, in which PTEN-null cells in
the primary tumor form “tumor’s prog-
eny” in the form of metastases. These
metastases may be more aggressive than
the primary tumor, because they do
not express PTEN. The primary tumor
then controls the growth of its “prog-
eny” through tumor suppressor (PTEN)
enriched microvesicles, which circulate in
the blood and keep PTEN-null metas-
tases in dormancy by supplementing them
with PTEN protein. This hypothesis may
explain the known phenomenon in which
removal of the primary tumor enhances
the growth of metastases, because the
source of the PTEN-bearing microvesicles
is removed.
On the other hand, microvesicles
enriched with oncogenic proteins may
be shed by tumor cells to oppose the
increased metabolic demand associated
with overexpression of oncogenic proteins.
Oncogenic protein expressing microvesi-
cles are also used as intercellular media-
tors to engage other cells (which may be
healthy) to provide a suitable growth niche
to nourish cancer cells. For example,EGFR-
bearing microvesicles stimulate endothelial
cells to secrete vascular endothelial growth
factor (VEGF) and the autophosphoryla-
tion of the VEGF receptor-2 (VEGFR2),
triggering the angiogenic switch to initiate
angiogenesis (1).
It is noteworthy that microvesicles
also contribute to the transfer of other
molecules such as mRNAs and miRNA
(miR), which can have various effects on
tumor progression by modulating tumor
microenvironment. An interesting cross-
talk was found between hepatocarcinoma
cells, whereby cells expressing miR-122
send this miR via microvesicles to inhibit
the proliferation of miR-122 deficient cells.
In a reciprocal process, miR-122 defi-
cient cells secrete insulin-like growth factor
to decrease miR-122 expression in miR-
122 expressing cells (13). Microvesicles
from cancer cells are found to stimulate
tumor-associated macrophages to secrete
VEGF, through the transfer of miR-150
(14) and thereby enhance tumorigenic-
ity. In an opposite effect, macrophages
inhibit proliferation of hepatocarcinoma
cells by transferring miR-142 and miR-
223 via microvesicles (15). A similar
effect is found for microvesicles from
marrow stromal cells expressing miR-146,
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which inhibit the proliferation of glioma
cells (16).
In this sense, the role of microvesi-
cles that contain molecules whose effects
are seemingly in opposition (oncoproteins,
oncomirs, or tumor suppressors) may be
reconciled from the perspective of the
tumor, a successful parasitic organ gener-
ated from our own cells. We realize that
this commentary may contain some spec-
ulations, but we hope that it can trigger
serious discussions in tumor biology,which
may contribute to the long battle against
the killer known as cancer.
ACKNOWLEDGMENTS
This work is supported by Prostate Cancer
Canada, Movember Foundation (grant no.
D2013-2: to Dr. K. Al-Nedawi).
REFERENCES
1. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC,
Rak J. Endothelial expression of autocrine VEGF
upon the uptake of tumor-derived microvesi-
cles containing oncogenic EGFR. Proc Natl Acad
Sci U S A (2009) 106:3794–9. doi:10.1073/pnas.
0804543106
2. Skog J, Wurdinger T, van Rijn S, Meijer DH,
Gainche L, Sena-Esteves M, et al. Glioblastoma
microvesicles transport RNA and proteins that
promote tumor growth and provide diagnostic
biomarkers. Nat Cell Biol (2008) 10:1470–6. doi:
10.1038/ncb1800
3. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May
L, Guha A, et al. Intercellular transfer of the onco-
genic receptor EGFRvIII by microvesicles derived
from tumour cells. Nat Cell Biol (2008) 10:619–24.
doi:10.1038/ncb1725
4. Gabriel K, Ingram A, Austin R, Kapoor A, Tang D,
Majeed F, et al. Regulation of the tumor suppressor
PTEN through exosomes: a diagnostic potential
for prostate cancer. PLoS One (2013) 8:e70047.
doi:10.1371/journal.pone.0070047
5. Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke
J, et al. The tumor suppressor PTEN is exported in
exosomes and has phosphatase activity in recip-
ient cells. Sci Signal (2012) 5:ra70. doi:10.1126/
scisignal.2003084
6. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Waka-
sugi T, et al. Loss of PTEN expression is associated
with colorectal cancer liver metastasis and poor
patient survival. BMC Gastroenterol (2008) 8:56.
doi:10.1186/1471-230X-8-56
7. Pettaway CA, Pathak S, Greene G, Ramirez
E, Wilson MR, Killion JJ, et al. Selection of
highly metastatic variants of different human
prostatic carcinomas using orthotopic implanta-
tion in nude mice. Clin Cancer Res (1996) 2:
1627–36.
8. Conley-LaComb MK, Saliganan A, Kandagatla
P, Chen YQ, Cher ML, Chinni SR. PTEN loss
mediated Akt activation promotes prostate tumor
growth and metastasis via CXCL12/CXCR4 sig-
naling. Mol Cancer (2013) 12:1–16. doi:10.1186/
1476-4598-12-85
9. Zhang LL, Liu J, Lei S, Zhang J, Zhou W, Yu
HG. PTEN inhibits the invasion and metasta-
sis of gastric cancer via downregulation of FAK
expression. Cell Signal (2014) 26:1011–20. doi:10.
1016/j.cellsig.2014.01.025
10. Gunduz N, Fisher B, Saffer EA. Effect of surgi-
cal removal on the growth and kinetics of residual
tumor. Cancer Res (1979) 39:3861–5.
11. Fisher B, Gunduz N, Saffer EA. Influence of the
interval between primary tumor removal and
chemotherapy on kinetics and growth of metas-
tases. Cancer Res (1983) 43:1488–92.
12. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E.
Presence of a growth-stimulating factor in serum
following primary tumor removal in mice. Cancer
Res (1989) 49:1996–2001.
13. Basu S, Bhattacharyya SN. Insulin-like growth
factor-1 prevents miR-122 production in
neighboring cells to curtail its intercellular trans-
fer to ensure proliferation of human hepatoma
cells. Nucleic Acids Res (2014) 42:7170–85.
doi:10.1093/nar/gku346
14. Liu Y, Zhao L, Li D, Yin Y, Zhang CY, Li J, et al.
Microvesicle-delivery miR-150 promotes tumori-
genesis by up-regulating VEGF, and the neutral-
ization of miR-150 attenuate tumor development.
Protein Cell (2013) 4:932–41. doi:10.1007/s13238-
013-3092-z
15. Aucher A, Rudnicka D, Davis DM. MicroR-
NAs transfer from human macrophages to
hepato-carcinoma cells and inhibit prolifera-
tion. J Immunol (2013) 191:6250–60. doi:10.4049/
jimmunol.1301728
16. Katakowski M, Buller B, Zheng X, Lu Y, Rogers
T, Osobamiro O, et al. Exosomes from marrow
stromal cells expressing miR-146b inhibit glioma
growth. Cancer Lett (2013) 335:201–4. doi:10.
1016/j.canlet.2013.02.019
Conflict of Interest Statement: The author declares
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 28 March 2014; accepted: 16 June 2014;
published online: 09 July 2014.
Citation: Al-Nedawi K (2014) The Yin–Yang of
microvesicles (exosomes) in cancer biology. Front. Oncol.
4:172. doi: 10.3389/fonc.2014.00172
This article was submitted to Molecular and Cellular
Oncology, a section of the journal Frontiers in Oncology.
Copyright © 2014 Al-Nedawi. This is an open-access
article distributed under the terms of the Creative Com-
mons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with
these terms.
Frontiers in Oncology | Molecular and Cellular Oncology July 2014 | Volume 4 | Article 172 | 2
